Sarcopenia Affects the Clinical Efficacy of Immune Checkpoint Inhibitors in Gastric Cancer Patients: a Systematic Review and Meta-Analysis

Key Points

• Sarcopenia significantly reduces the clinical efficacy of immune checkpoint inhibitors in gastric cancer patients.
• In tumors, 60% of patients with sarcopenia respond poorly to immune therapy as per the analysis of multiple studies.
• A systematic review and meta-analysis that included data on clinical outcomes and muscle mass demonstrated these findings clearly.
• The findings may inform treatment strategies for better outcomes in gastric cancer patients, particularly those with low muscle mass.